Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$122.7M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
710.08%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$198.9M
Q3 2024
Cash
Q3 2024
P/E
-4.713
Nov 29, 2024 EST
Free Cash Flow
-$96.70M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018
Selling, General & Admin $18.82M $24.71M $20.39M $7.820M $400.0K $390.0K
YoY Change -23.84% 21.2% 160.75% 1855.0% 2.56%
% of Gross Profit
Research & Development $86.14M $82.27M $51.10M $13.70M $3.920M $1.690M
YoY Change 4.7% 61.01% 272.88% 249.59% 131.95%
% of Gross Profit
Depreciation & Amortization $377.0K $357.0K $163.0K $11.00K $9.000K $10.00K
YoY Change 5.6% 119.02% 1381.82% 22.22% -10.0%
% of Gross Profit
Operating Expenses $105.0M $107.0M $71.49M $21.53M $4.323M $2.080M
YoY Change -1.89% 49.65% 232.08% 397.99% 107.84%
Operating Profit -$105.0M -$107.0M -$71.49M -$21.53M -$4.323M
YoY Change -1.89% 49.65% 232.08% 397.99%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018
Interest Expense $8.325M $2.228M $442.0K $653.0K $10.00K -$20.00K
YoY Change 273.65% 404.07% -32.31% 6430.0% -150.0%
% of Operating Profit
Other Income/Expense, Net -$19.00K $2.201M $395.0K -$593.0K $7.000K $0.00
YoY Change -100.86% 457.22% -166.61% -8571.43%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018
Pretax Income -$96.66M -$104.8M -$71.10M -$22.12M -$4.320M -$2.200M
YoY Change -7.76% 47.39% 221.41% 412.04% 96.36%
Income Tax $2.000K $1.000K
% Of Pretax Income
Net Earnings -$96.66M -$104.8M -$71.10M -$22.12M -$4.316M -$2.200M
YoY Change -7.76% 47.39% 221.4% 412.53% 96.18%
Net Earnings / Revenue
Basic Earnings Per Share -$2.14 -$2.62 -$1.80 -$3.42 -$1.66
Diluted Earnings Per Share -$2.14 -$2.62 -$1.80 -$3.42 -$1.66 -$57.11K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018
Cash & Short-Term Investments $261.8M $204.4M $287.3M $338.5M $100.0K $3.100M
YoY Change 28.07% -28.84% -15.14% 338400.0% -96.77%
Cash & Equivalents $68.54M $23.70M $13.81M $338.5M $100.0K $3.100M
Short-Term Investments $193.3M $180.7M $273.4M
Other Short-Term Assets $4.033M $4.159M $3.435M $3.500M $0.00 $100.0K
YoY Change -3.03% 21.08% -1.86% -100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $266.5M $208.9M $290.7M $342.1M $100.0K $3.200M
YoY Change 27.58% -28.14% -15.03% 342000.0% -96.88%
Property, Plant & Equipment $3.259M $3.975M $4.720M $100.0K $0.00 $0.00
YoY Change -18.01% -15.78% 4620.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.173M $2.771M $540.0K $500.0K $0.00 $0.00
YoY Change 158.86% 413.15% 8.0%
Total Long-Term Assets $10.43M $6.746M $5.260M $600.0K $0.00 $100.0K
YoY Change 54.64% 28.25% 776.67% -100.0%
Total Assets $276.9M $215.6M $295.9M $342.7M $100.0K $3.300M
YoY Change
Accounts Payable $2.698M $374.0K $23.00K $700.0K $900.0K $100.0K
YoY Change 621.39% 1526.09% -96.71% -22.22% 800.0%
Accrued Expenses $18.85M $16.02M $8.530M $3.500M $0.00 $0.00
YoY Change 17.63% 87.87% 143.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $21.62M $16.55M $9.019M $4.600M $1.400M $200.0K
YoY Change 30.65% 83.49% 96.07% 228.57% 600.0%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.429M $1.550M $2.358M
YoY Change -7.81% -34.27%
Total Long-Term Liabilities $1.429M $1.550M $2.358M $0.00 $0.00 $0.00
YoY Change -7.81% -34.27%
Total Liabilities $23.05M $18.10M $11.38M $4.600M $1.400M $200.0K
YoY Change 27.36% 59.08% 147.33% 228.57% 600.0%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018
Basic Shares Outstanding 45.25M 40.00M 39.52M 7.021M 2.593M
Diluted Shares Outstanding 45.25M 40.00M 39.52M 7.021M 2.593M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $578.14 Million

About Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. The company is headquartered in San Francisco, California and currently employs 87 full-time employees. The company went IPO on 2020-11-19. The firm is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The firm's OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including ESR1 and PIK3CA mutations and central nervous system (CNS), metastasis. The company is in the Phase I/ II clinical trial, and in Phase Ib/ II combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Industry: Pharmaceutical Preparations Peers: Astria Therapeutics, Inc. AVITA Medical, Inc. DermTech, Inc. Inmune Bio, Inc. Syros Pharmaceuticals, Inc. Nuvectis Pharma, Inc. PepGen Inc. Oric Pharmaceuticals, Inc. Praxis Precision Medicines, Inc.